Huwidi Ali, Abobrege Afaf, Assidi Mourad, Buhmeida Abdelbaset, Ermiah Eramah
Department of Gynaecology, National Cancer Institute, Misurata University, Misurata 051, Libya.
Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Makkah 21589, Saudi Arabia.
Mol Clin Oncol. 2022 May 30;17(1):118. doi: 10.3892/mco.2022.2551. eCollection 2022 Jul.
In the present study, the Risk Malignancy Index (RMI) was calculated based on menopausal status, ultrasound (US) findings and serum biological cancer antigen 125 (CA-125) levels as a scoring system in Libyan females with ovarian masses (OMs) to differentiate between benign and malignant tumors. A total of 51 females with OMs referred to the Gynaecology Department of the National Cancer Institute in Misurata (Libya) between January 2019 and December 2020 were retrospectively reviewed for diagnostic testing. Clinicopathological and demographic data were obtained from patient records. A cut-off point of RMI=200 was used to differentiate between benign and malignant tumors. The mean age of the patients was 47 years (range, 19-90 years) and 60% of the patients were premenopausal. Examination of the four RMI indices and disease status indicated that the association with the US score (P<0.0001) and with CA-125 (P=0.017) was highly significant. However, the age at diagnosis and menopausal status did not have any significant association with the disease status. The RMI with a cut-off point of 200 had a sensitivity and specificity of 87.5 and 90.7%, respectively, and a positive and negative predictive value of 63.6 and 97.5%, respectively. The association between the RMI and disease status was highly significant (P<0.0001). In conclusion, the RMI appears to be a reliable, simple and cost-effective tool for clinical differentiation between benign and malignant OMs. This may help to improve the optimal diagnosis and planning of an individualized treatment strategy. However, given the small sample size of the cohort, further validation using larger cohorts in other settings is recommended.
在本研究中，风险恶性指数（RMI）基于绝经状态、超声（US）检查结果和血清癌胚抗原125（CA-125）水平进行计算，作为利比亚卵巢肿块（OM）女性的一种评分系统，用于区分良性和恶性肿瘤。回顾性分析了2019年1月至2020年12月期间转诊至米苏拉塔（利比亚）国家癌症研究所妇科的51例OM女性患者的诊断检查情况。从患者记录中获取临床病理和人口统计学数据。采用RMI=200的截断点来区分良性和恶性肿瘤。患者的平均年龄为47岁（范围19 - 90岁），60%的患者为绝经前。对四个RMI指标与疾病状态的检查表明，与US评分（P<0.0001）和CA-125（P=0.017）的关联高度显著。然而，诊断时的年龄和绝经状态与疾病状态没有显著关联。截断点为200的RMI的敏感性和特异性分别为87.5%和90.7%，阳性和阴性预测值分别为63.6%和97.5%。RMI与疾病状态之间的关联高度显著（P<0.0001）。总之，RMI似乎是一种可靠、简单且具有成本效益的工具，可用于临床区分良性和恶性OM。这可能有助于改善个体化治疗策略的最佳诊断和规划。然而，鉴于该队列样本量较小，建议在其他环境中使用更大的队列进行进一步验证。
